Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine

Worldwide, hepatitis C virus (HCV) is a common infection. Due to new antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy has become more comfortable. Nevertheless, there are special patient groups, in whom treatment of HCV is still challenging. Due to only few...

Authors: Hüsing, Anna Katharina Elisabeth Pia
Kabar, Iyad
Schmidt, Hartmut
Heinzow, Hauke S.
Division/Institute:FB 05: Medizinische Fakultät
Document types:Article
Media types:Text
Publication date:2015
Date of publication on miami:01.12.2015
Modification date:16.04.2019
Edition statement:[Electronic ed.]
Source:International Journal of Molecular Sciences (IJMS) 16 (2015) 8, 18033-18053
Subjects:HCV infection; chronic kidney disease; renal transplantation; decompensated liver cirrhosis; liver transplantation; new therapy regimen; DAA treatment
DDC Subject:610: Medizin und Gesundheit
License:CC BY 4.0
Language:English
Notes:Finanziert durch den Open-Access-Publikationsfonds 2015/2016 der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF document
ISSN:1422-0067
URN:urn:nbn:de:hbz:6-37269443268
Permalink:http://nbn-resolving.de/urn:nbn:de:hbz:6-37269443268
Other Identifiers:DOI: 10.3390/ijms160818033
Digital documents:ijms-16-18033.pdf

Worldwide, hepatitis C virus (HCV) is a common infection. Due to new antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy has become more comfortable. Nevertheless, there are special patient groups, in whom treatment of HCV is still challenging. Due to only few data available, tolerability and efficacy of DAAs in special patient cohorts still remain unclear. Such special patient cohorts comprise HCV in patients with decompensated liver disease (Child-Pugh Class B or C), patients with chronic kidney disease, and patients on waiting lists to renal/liver transplantation or those with HCV recurrence after liver transplantation. HCV infection in these patient cohorts has been shown to be associated with increased morbidity and mortality and may lead to reduced graft survival after transplantation. Successful eradication of HCV results in a better outcome concerning liver-related complications and in a better clinical outcome of these patients. In this review, we analyze available data and results from recently published literature and provide an overview of current recommendations of HCV-therapy regimen in these special patient cohorts.